Previous 10 | Next 10 |
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17 th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2 Diabetes Patients in COVALENT-111 are displaying improved glycemic cont...
REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...
2024-02-18 18:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-06 08:21:48 ET Gainers: Helius Medical Technologies ( HSDT ) +38% Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients. Chenghe Acquisition ( CHEA ) +22% . Palantir Technologies ( PLTR ) +18% ...
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024. Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Biomea ...
The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada. Eligible patients include those who have been diagnosed with type 1 diabetes for up to 15 years. Data from the Phase II study are expected in 2024. REDWOOD CITY, ...
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically define...
2023-12-13 02:51:56 ET Summary Biomea Fusion's BMF-219 shows potential in diabetes but lags in efficacy compared to competitors. Increased R&D expenses led to higher operating losses and share dilution, but the company maintains a strong current ratio. Market sentiment is ...
2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
2024-05-09 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healt...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...